Objective: Plantar fasciitis is one of the most common musculoskeletal diseases, and nearly 90% of patients can be successfully treated by nonsurgical options. However, it is yet to be determined which nonsurgical treatment has the best efficacy. The present study investigated differences between autologous blood-derived products and corticosteroid injections in the treatment of plantar fasciitis. TYPE: Systematic Review and Meta-analysis.
Literature Survey: PubMed, EMBASE, CINAHL, and Web of Science were searched for relevant articles up to November 2019. There was no language restriction, and unpublished trials were excluded. This systematic review included only randomized controlled trials.
Methodology: The primary outcomes were Visual Analog Scale and American Orthopedic Foot and Ankle Score (AOFAS). The follow-up times were divided into short term (3-6 weeks), intermediate term (3 months or 12 weeks), and long term (6 months or 24 weeks). The random-effects model was utilized, and weighted mean difference was calculated as the pool estimates.
Synthesis: Thirteen randomized controlled trials and 640 patients were included. No significant difference in Visual Analog Scale reduction was observed between autologous blood-derived product and corticosteroid injections in the short term (weighted mean difference [WMD] = -0.84; 95% confidence interval [CI], -1.71 to 0.03; P = .057), intermediate term (WMD = -0.24; 95% CI, -0.90 to 0.42; P = .475), and long term (WMD = 0.47; 95% CI, -0.72 to 1.65; P = .44). No significant difference in AOFAS was observed between autologous blood-derived products and corticosteroids in the short term (WMD = -0.65; 95% CI, -5.40 to 4.10; P = .79), intermediate term (WMD = 0.17; 95% CI, -8.07 to 8.41; P = .97), and long term (WMD = 1.16; 95% CI, -4.54 to 6.86; P = .69).
Conclusions: This systematic review and meta-analysis of autologous blood-derived products versus corticosteroids for plantar fasciitis is the first that includes only randomized controlled trials. The meta-analysis found no significant difference between autologous blood-derived products and corticosteroids, as measured by Visual Analog Scale or AOFAS. These findings applied whether followed up in short, intermediate, or long term. These results differ from previous studies that showed superior efficacy of autologous blood-derived products compared with corticosteroids in the long term.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pmrj.12373 | DOI Listing |
Exp Eye Res
December 2024
Department of Medical Physics, Radiobiology and Radiation Protection, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Dry eye disease (DED) is a common ocular condition characterized by chronic inflammation and tear film disruption. It affects millions of people worldwide, causing significant eye discomfort and vision disturbances. Despite its prevalence, DED remains a complex condition that is not yet fully understood.
View Article and Find Full Text PDFEBioMedicine
December 2024
Monash Newborn, Monash Children's Hospital, Melbourne, Australia; Department of Paediatrics, Monash University, Melbourne, Australia; The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia. Electronic address:
Background: Evidence from preclinical studies in small and large animal models has shown neuroprotective effects of intravenous administration of umbilical cord blood derived cells (UCBCs). This study aimed to evaluate the feasibility of umbilical cord blood (UCB) collection, extraction of UCBCs, and subsequent safety of intravenous autologous administration of UCBCs in extremely preterm infants (born <28 weeks gestation).
Methods: A single-centre, open-label, single-arm, safety and feasibility clinical intervention trial was conducted at Monash Medical Centre and Monash Children's Hospital, Melbourne, Australia.
Indian J Orthop
December 2024
South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX 78045 USA.
Introduction: Non-union fractures represent a significant challenge in orthopedic practice, contributing to considerable morbidity and socioeconomic burden. Traditional treatments, such as autologous bone grafting, are effective but have limitations, including donor-site morbidity and limited tissue availability. Autologous peripheral blood-derived orthobiologics, including growth factor-rich concentrate (GFC), have emerged as a minimally invasive alternative, leveraging the body's natural healing mechanisms by concentrating and applying growth factors directly to the fracture site.
View Article and Find Full Text PDFCureus
November 2024
Department of Regenerative Medicine, Future Biologics, Lawrenceville, USA.
Gold-induced cytokine (GOLDIC) is a novel orthobiologic approach utilizing gold particles to produce a serum rich in immunoregulating cytokines and growth factors, which is being explored for its potential in tissue regeneration and treating musculoskeletal issues like knee osteoarthritis (OA). This study aims to review its mechanism of action along with the outcomes of , preclinical, and clinical studies, with a secondary focus on documenting clinical trials related to its use in OA of the knee. A systematic search was conducted in four databases (Embase, Scopus, PubMed, Web of Science) for studies on GOLDIC therapy for knee OA, using specific keywords related to knee anatomy and OA.
View Article and Find Full Text PDFCell Reprogram
December 2024
USM-ALPS Cardiac Research Laboratory, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia.
Cord blood (CB) is widely stored as a source of hematopoietic stem cells for potential future use, though its application for autologous purposes remains limited. Repurposing CB into human-induced pluripotent stem cells (hiPSCs) can broaden its utility beyond hematological conditions. This study investigated the effects of umbilical cord-mesenchymal stromal cell (UC-MSC) co-culture on CB CD34 cells and the characteristics of the resulting hiPSCs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!